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ture and the volume of his professional activity, the effects of the
competition and locals’ standards. RESULTS: The behaviour of
the prescription of the physician depend of his type of conven-
tion with the State. At the average, the physicians, who do not
have the convention, prescribe 41 Euro of drugs per act, the
physicians, who have the price of consultation ﬁxed by the State,
prescribe 36 Euro per act and the physicians, who can ﬁx freely
their price, prescribe 30€ per act. The prescription is a regulator
of the level of activity (-3.65 for the physicians without the con-
vention, 0.02 for the rest). We ﬁnd an effect of complement
between the pharmaceutical prescription and the prescription of
sick leaves’ days. Competition has the inﬂuence upon the level
of the regulation. CONCLUSIONS: The result of this study
makes possible to deﬁne the inciting policies on the pharmaceu-
tical regulation to ensure a greater effectiveness of the regulation
of an ambulatory medicine.
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OBJECTIVES: In Australia, a drug is subsidised by the govern-
ment only if the Pharmaceutical Beneﬁts Advisory Committee
(PBAC) evaluation has determined the drug to be cost effective.
The government reviewed the quality of industry pharmacoeco-
nomic analyses included in PBAC submission documents and
reported that signiﬁcant problems existed. It is likely, however,
that the PBAC evaluation process itself could contain errors. We
sought to determine the quality of the PBAC evaluations, their
effect on decision-making and the outcomes of PBAC meetings.
METHODS: A survey was conducted to determine industry
experience regarding PBAC decision-making over a period of six
PBAC meetings. The questionnaire was designed to elicit infor-
mation on good and poor decisions, and information needed to
quantify the issues and their effects on submission outcomes. The
questionnaire was divided into 2 sections, the ﬁrst to elicit infor-
mation on good and poor decisions and the second to quantify
the issues and their effects on submission outcomes. RESULTS:
Of 35 questionnaires sent to pharmaceutical companies in 
Australia, 17 replies were received, a response rate of 48%.
These 17 companies had sales that represented 47% of total
pharmaceutical sales. The survey concluded that on average
good decisions were made by the PBAC for only 56% of all sub-
missions. The quality of the PBAC evaluation was related to the
form of economic argument presented and whether the submis-
sion was a ﬁrst or a subsequent (repeat) submission. If the sub-
mission used a cost-minimisation approach, the likelihood of the
evaluation being good was 69%, compared with 38% for sub-
missions that took a cost-effectiveness approach. The likelihood
of a submission’s success was also related to the form of eco-
nomic analysis used, 92% if cost-minimisation was used versus
63% for a cost-effectiveness approach. CONCLUSIONS: Gov-
ernment subsidy decision-making is of variable quality, which
varies the method of economic argument used and affects the
probability of success for submissions.
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OBJECTIVE: Literature suggests that ‘Academic Detailing’ is a
useful ‘evidence-based’ intervention in promoting rational drug
therapy by encouraging appropriate use of cost-effective generic
pharmaceuticals. This study examines possible impact of acade-
mic detailing on trends in change of proportions of generic drug
prescriptions among ambulatory care physicians serving patients
covered by a state health insurance program. METHODS: The
study was conducted using retrospective data available from the
pharmacy beneﬁt management company serving the insurance
program. The target physician population comprised of two
experimental groups (Charleston, n = 251; Morgantown, n =
214)—the top 30th percentile of all the physicians in the areas
chosen based on prescribing volume and average prescription
cost. University-trained academic detailers visited them once
every month and also provided them with educational materials.
A “comparison” group (n = 359) was chosen similarly but was
not visited by a detailer at any time. Monthly generic prescrib-
ing percent were determined for all three groups for a period of
12 months before the intervention and 6 months after the inter-
vention. Two therapeutic classes with ample generic choices—
antibiotics and anti-hypertensives, were studied. RESULTS: In
case of antibiotic prescriptions, while mean increase in percent
generic prescriptions went up in both the experimental groups
(0.26 to 2.41 in Charleston; -0.18 to 2.35 in Morgantown),
mean change in percentage generic prescriptions reduced further
(-0.6 to -3.36) in the comparison group. Though over a much
shorter intervention period—similar trends were observed with
anti-hypertensive prescriptions. In Charleston, there was a sus-
tained (mean rate of change over intervention period = 1.37)
trend in increase in proportion of generic prescriptions while the
proportion declined in the comparison group (mean rate of
change over intervention period = -0.44). CONCLUSIONS:
Academic detailing appears to be a promising strategy for main-
taining or increasing generic prescribing by physicians in ambu-
latory settings.
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OBJECTIVES: The Guidelines is a guidance document to assist
those doing economic evaluations produce standardized and 
reliable economic information for the users of the information
(e.g. decision-makers in Canada’s publicly-funded health care
system). The main changes in this 3rd edition will be discussed.
METHODS: CCOHTA has revised the 1997 edition of the
Guidelines to ensure it remains current, taking into account of
methodological developments and other signiﬁcant changes since
1997. Each Guideline section provides guidance on preferred
methods and advice in areas of controversy. Key stakeholders,
including jurisdictions, industry and methodological experts,
were consulted. Judgement was needed to strike the proper
balance between theoretically ideal vs pragmatic approaches.
RESULTS: Key changes include emphasis on: 1) using cost-
effectiveness and cost-utility analyses; 2) presenting the payer
perspective; 3) using “usual” and recommended care for the
comparator; 4) appropriate analysis of effectiveness parameters;
4) using probabilistic and Bayesian analyses for analyzing uncer-
tainty; 6) using stratiﬁed analysis; and 7) identifying distribu-
tional effects of the technology. Appendices include: 1) guidance
on evaluating non-drug technologies; 2) changes to the stan-
dardized reporting format; 3) guidance on modelling; 4) guid-
ance on reviewing economic studies; 5) quality assurance tips for
doers; and 6) tips for decision-makers on the use and interpre-
